Revium Rx.

Revium Rx is a pre-clinical stage biopharmaceutical company developing and commercializing innovative nanoparticle-based therapies. The company focuses on creating targeted treatments to improve how medicines work, aiming to increase effectiveness and reduce side effects. Revium Rx is developing unique lipid-based platforms for various uses, including antimicrobial resistance and solid tumors. The company's work is inspired by Prof. Barenholz, an innovator in nano-medicine and liposomal drug delivery. Revium Rx's programs focus on infectious diseases, including antibiotic-resistant infections, solid tumors, and a novel vaccination approach. The company uses advanced lipid-based delivery systems to enhance the safety, efficacy, and clinical utility of established therapeutics, and explores new uses for existing compounds. Its proprietary technology builds on principles demonstrated by liposomal drug delivery products like Doxil®, the first FDA-approved nanomedicine. By encapsulating therapeutics in lipid-based particles, Revium Rx aims to enable controlled release, improve biodistribution to diseased tissues, and extend systemic circulation time. These enhancements are intended to improve the therapeutic index by increasing efficacy at the disease site while potentially reducing systemic exposure and associated toxicities. Planned clinical trials will evaluate if this approach can expand treatment options for conditions with significant unmet medical need, such as antimicrobial resistance and solid tumors. The company's core business strategy combines disciplined product candidate development with internal expertise and external resources.